Tumour-informed liquid biopsies to monitor advanced melanoma patients under immune checkpoint inhibition

Christopher Schroeder, Andrea Forschner(University of Tübingen), Jakob Admard(University of Tübingen), Olga Kelemen(University of Tübingen), Irina Bonzheim(University Children's Hospital Tübingen), Brigitte Gückel(University Children's Hospital Tübingen), Francesc Muyas(European Bioinformatics Institute), Sorin Armeanu–Ebinger(University Children's Hospital Tübingen), Thomas Küstner(TH Bingen University of Applied Sciences), Peter Martus(University of Tübingen), Sergios Gatidis(University of Tübingen), Christina Pfannenberg(University Children's Hospital Tübingen), Lukas Flatz(Leman University), Claus Garbe(University of Tübingen), Stephan Ossowski(University of Southern California), Leon Schütz(University of Tübingen)
Nature Communications
October 9, 2024
10.1038/s41467-024-52923-0
Cited by 19

Related Papers

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2016|1k
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
|The Lancet Oncology|2014|978